Willingness to participate in HIV-1 vaccine trials among young Thai men

R A Jenkins, K Torugsa, L E Markowitz, C J Mason, V Jamroentana, A E Brown, S Nitayaphan

Objectives: Willingness to participate in HIV-1 vaccine trials and associated factors were investigated in a sample of 2670 Royal Thai Army conscripted recruits.

Methods: Self-administered questionnaires were used. Data were collected during the final visit of a longitudinal cohort study of HIV-1 epidemiology. Cross-sectional analysis of data from this visit was performed.

Results: 32% of the respondents reported they would “definitely” join an HIV-1 vaccine trial. Greater willingness was associated with perceived risk of HIV-1 infection and a desire to help Thai society, although tangible incentives and intentions to reduce condom use in a vaccine trial also were associated with increased willingness. Concerns about physical harm and anticipated social pressure from family not to join were the most substantial impediments to willingness. Concerns about “social harm” (for example, participation would give appearance of having AIDS virus, a partner might refuse sex) also appeared to inhibit interest in joining trials and approached significance.

Conclusions: Willingness to participate was somewhat greater than in other investigations of non-injection drug user (IDU) cohorts in Thailand, with fewer concerns expressed about physical harm. Motivations appear to involve tradeoffs among perceived risk, anticipated social pressure, altruism, and tangible rewards. The absence of significant problems associated with vaccine trials to date, along with the presence of educational interventions in the study may help explain the lower level of concerns here relative to other Thai studies.

Keywords: HIV; vaccine; Thailand

Introduction

A growing body of literature has investigated willingness to participate in preventive HIV-1 vaccine trials. Besides providing estimates of interest, assessing willingness may identify conditions which foster or inhibit the motivation to join trials, as well as identify important population differences. Thailand is one of several countries where preparations for HIV-1 vaccine efficacy trials have been under way and a number of studies of willingness to participate in trials have taken place. One study in Thailand, conducted with medical centre employees who had received an informational briefing about a proposed trial, found that only 6.3% were willing to take part, although 40.4% reported at least some interest in joining. Subsequent studies have found that 25–51% of participants would definitely join such a trial. Unlike the medical centre study, these other investigations were epidemiological cohort investigations of HIV-1 incidence to evaluate the feasibility of HIV-1 vaccine trials and were conducted in populations believed to be at elevated risk. Seroprevalence in these investigations varied from 2.5% to 38.3% and incidence ranged from 0.0/100 person years to 8.1/100 person years. With one exception, participants in these studies did not receive vaccine trial education before their willingness was assessed. Regardless of the population studied in Thailand, concerns about vaccine product safety and “social harm” (for example, participation would give appearance of having AIDS virus, a partner might refuse sex) have emerged as significant barriers to joining trials.

Several questions about willingness to participate emerge from reviewing previous studies from Thailand. Both the highest and lowest levels of willingness occurred where education was provided and self-administered questionnaires were used; however, the sample with the lowest willingness was drawn from a population not considered to be at elevated HIV-1 risk. The greatest willingness occurred in a sample of in-treatment injection drug users (IDU) who had stable prevalence levels of over 30%; hence, it is unclear whether population characteristics matter as much as data collection methodology or education concerning vaccine trials.

The present investigation evaluated willingness to participate in HIV-1 preventive vaccine trials using a self-administered questionaire in Royal Thai Army (RTA) recruits. These young Thai men were participants in a longitudinal epidemiological cohort study of HIV-1 incidence. General information about HIV-1 vaccine was provided as part of didactic and small group behavioural interventions. In addition, the investigation assessed risk relevant behaviour, HIV-1 knowledge, and attitudes regarding HIV-1 prevention practices, factors which have not been assessed in most previous investigations of willingness in Thailand or elsewhere.

Methods

PARTICIPANTS A total of 2674 HIV-1 seronegative RTA conscripted soldiers participated in the assess-
RESULTS

WILLINGNESS TO PARTICIPATE IN VACCINE TRIALS

At entry into the RTA (2 years before data collection), the study participants had been predominantly 21 years old (93.7%), single (75.2%), and had the national norm of 6 years or less of education (75.6%). Most (60.4%) had been living in rural areas before joining the military. Nearly half had been living in northeastern Thailand before entering the military, while one quarter had been living in the Greater Bangkok area, and the remainder had resided in the lower central or upper southern regions. The sample available for analysis included 70.9% of those who had participated in the incidence study at baseline. This proportional loss to follow up was similar to that found in other research with RTA recruits and occurred for similar reasons (for example, reassignment after initial basic training). The sample available for follow up did not significantly differ from the rest of the cohort in terms of key baseline variables (that is, sociodemographics, age at first sex, CSW experience, condom use, IDU experience, alcohol use). HIV-1 prevalence in the initial sample was 1.8%, while incidence was 0.46/100 person years in those available for follow up.

WILLINGNESS TO PARTICIPATE IN VACCINE TRIALS

Overall, 32.0% indicated they would “definitely” be willing to join an HIV-1 vaccine trial. Another 12.9% said they were “very likely” to join and 45.0% said they might join. In

Table 1 Univariate analysis of sociodemographic characteristics and willingness to join an HIV vaccine trial (n=2674; overall, 32.0% were “definitely willing to join” a vaccine trial)

<table>
<thead>
<tr>
<th>Variable</th>
<th>N</th>
<th>%</th>
<th>OR</th>
<th>95% CI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at induction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22-29 years (n=1699)</td>
<td>55</td>
<td>32.5</td>
<td>1.03</td>
<td>0.82-1.29</td>
<td>0.87</td>
</tr>
<tr>
<td>21 years (n=2498)</td>
<td>797</td>
<td>31.9</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at 1st sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤15 years (n=626)</td>
<td>206</td>
<td>32.9</td>
<td>1.04</td>
<td>0.92-1.19</td>
<td>0.53</td>
</tr>
<tr>
<td>&gt;15 years (n=2002)</td>
<td>633</td>
<td>31.6</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marital status at induction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single (n=2005)</td>
<td>639</td>
<td>31.9</td>
<td>0.99</td>
<td>0.87-1.13</td>
<td>0.89</td>
</tr>
<tr>
<td>Married (n=661)</td>
<td>213</td>
<td>32.2</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Domicile—during 2 years before induction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban (n=1053)</td>
<td>302</td>
<td>28.7</td>
<td>0.84</td>
<td>0.75-0.94</td>
<td>0.003</td>
</tr>
<tr>
<td>Rural (n=1609)</td>
<td>558</td>
<td>34.2</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Region of residence—during 2 years before induction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>North east (n=1184)</td>
<td>446</td>
<td>37.7</td>
<td>1.37</td>
<td>1.23-1.53</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Other regions (n=1480)</td>
<td>406</td>
<td>27.4</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

www.sextransinf.com
Table 2  Frequencies of endorsement: concerns about participating in an HIV vaccine trial and possible incentives (n=2674)

<table>
<thead>
<tr>
<th>Concerns:</th>
<th>Yes</th>
<th>No</th>
<th>Not sure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical harm index items:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Side effects from vaccine injections</td>
<td>20.8%</td>
<td>31.6%</td>
<td>47.5%</td>
</tr>
<tr>
<td>Long term side effects</td>
<td>18.0%</td>
<td>33.7%</td>
<td>48.3%</td>
</tr>
<tr>
<td>Getting AIDS from the vaccine</td>
<td>13.9%</td>
<td>48.5%</td>
<td>37.6%</td>
</tr>
<tr>
<td>Handicap or death from the vaccine</td>
<td>15.0%</td>
<td>52.9%</td>
<td>34.1%</td>
</tr>
<tr>
<td>Becoming sick sooner if I ever get AIDS virus</td>
<td>17.6%</td>
<td>47.2%</td>
<td>35.2%</td>
</tr>
<tr>
<td>AIDS vaccine might contain AIDS virus</td>
<td>11.3%</td>
<td>52.3%</td>
<td>36.3%</td>
</tr>
<tr>
<td>Social harm index items:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taking part may be seen has having AIDS</td>
<td>15.1%</td>
<td>56.1%</td>
<td>28.9%</td>
</tr>
<tr>
<td>Wife/partner might refuse sexual relations</td>
<td>15.3%</td>
<td>50.2%</td>
<td>34.5%</td>
</tr>
<tr>
<td>Other concerns (not included in indices):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>My family may not want me to take part</td>
<td>15.3%</td>
<td>52.5%</td>
<td>32.2%</td>
</tr>
<tr>
<td>Having to sign a consent form</td>
<td>9.8%</td>
<td>63.6%</td>
<td>26.6%</td>
</tr>
<tr>
<td>Time necessary to be in a medical study</td>
<td>9.5%</td>
<td>67.1%</td>
<td>23.4%</td>
</tr>
</tbody>
</table>

Incentives:

Tangible incentives:
- Lump sum payment (5000 baht cash)* | 6.1% | 67.8% | 26.3% |
- Health insurance for 5 years | 27.8% | 39.3% | 32.9% |
- Medical care for 5 years | 31.8% | 35.2% | 33.0% |
- Reimbursement for travel to vaccine clinic | 15.7% | 50.9% | 33.4% |
- Recognition from family or friends | 39.4% | 28.0% | 32.6% |

Other incentives:
- Knowing you help Thai society | 43.2% | 28.6% | 28.2% |
- Would not want any incentive | 45.4% | 22.4% | 32.2% |

* $200 at the time of data collection; approximately 150% of the minimum wage for 1 month, for those living outside of Bangkok (125% of the Bangkok minimum wage).

Table 3  Univariate analysis of incentives and concerns associated with willingness to join an HIV vaccine trial (n=2674)

<table>
<thead>
<tr>
<th>“Definitely willing to join”</th>
<th>No</th>
<th>%</th>
<th>OR 95% CI p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical harm concerns (composite)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1+ endorsements (yes/not sure) (n=2171)</td>
<td>623</td>
<td>28.7</td>
<td>0.62</td>
</tr>
<tr>
<td>None (n=503)</td>
<td>233</td>
<td>46.3</td>
<td>1.00</td>
</tr>
<tr>
<td>Social harm concerns (composite)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1+ endorsements (yes/not sure) (n=1950)</td>
<td>400</td>
<td>25.8</td>
<td>0.64</td>
</tr>
<tr>
<td>None (n=1112)</td>
<td>457</td>
<td>40.7</td>
<td>1.00</td>
</tr>
<tr>
<td>Time necessary to be in a medical study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (n=1880)</td>
<td>198</td>
<td>22.5</td>
<td>0.61</td>
</tr>
<tr>
<td>No (n=1794)</td>
<td>658</td>
<td>36.7</td>
<td>1.00</td>
</tr>
<tr>
<td>Having to sign a consent form</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (n=973)</td>
<td>225</td>
<td>23.1</td>
<td>0.62</td>
</tr>
<tr>
<td>No (n=1701)</td>
<td>633</td>
<td>37.2</td>
<td>1.00</td>
</tr>
<tr>
<td>My family may not want me to take part</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (n=1267)</td>
<td>276</td>
<td>21.8</td>
<td>0.53</td>
</tr>
<tr>
<td>No (n=1407)</td>
<td>581</td>
<td>41.3</td>
<td>1.00</td>
</tr>
<tr>
<td>Tangible incentives (composite)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1+ endorsements (yes) (n=1037)</td>
<td>416</td>
<td>40.1</td>
<td>1.49</td>
</tr>
<tr>
<td>None (n=1637)</td>
<td>440</td>
<td>26.9</td>
<td>1.00</td>
</tr>
<tr>
<td>Recognition from family or friends</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (n=1053)</td>
<td>439</td>
<td>41.7</td>
<td>1.62</td>
</tr>
<tr>
<td>No (n=1621)</td>
<td>418</td>
<td>25.8</td>
<td>1.00</td>
</tr>
<tr>
<td>Knowing you help Thai society</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (n=1157)</td>
<td>492</td>
<td>42.5</td>
<td>1.77</td>
</tr>
<tr>
<td>No (n=1517)</td>
<td>366</td>
<td>24.1</td>
<td>1.00</td>
</tr>
<tr>
<td>Would not want any incentive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (n=580)</td>
<td>196</td>
<td>33.8</td>
<td>1.07</td>
</tr>
<tr>
<td>No (n=2094)</td>
<td>662</td>
<td>31.6</td>
<td>1.00</td>
</tr>
</tbody>
</table>

1 = See table 2 for content of composite index.

contrast, 6.7% said they would “very likely not join” and 3.3% would “definitely not join.”

SOCIODEMOGRAPHIC FACTORS AND WILLINGNESS TO PARTICIPATE

Univariate analyses indicated that education and region of residence before entry into the army were related to willingness to participate (table 1). Those with a primary school education (or less) were significantly more willing to participate, as were participants who had been living in northeast Thailand before entering the RTA. Those who had been living in urban areas before their military service reported less willingness to participate in vaccine trials than those from rural areas.

Table 4 summarises univariate odds ratios and 95% confidence intervals for concerns and incentives related to vaccine trial participation.

Frequencies of responses regarding potential concerns and incentives are noted in table 2. Major concerns regarding HIV-1 vaccine trial participation involved vaccine side effects and anticipated social pressure from family not to join. Many indicated they were “not sure” regarding safety risks, particularly injection related side effects and possible long term side effects. The most frequently endorsed incentives involved helping Thai society and recognition from family and friends. Medical care and insurance also received frequent endorsement and were chosen more often than receiving a lump sum monetary payment. Although nearly a half of the recruits endorsed an item that indicated a willingness to accept no incentive, many of these respondents did, in fact, endorse some tangible incentive. Controlling for these other endorsements, only 21.7% appeared to truly want no incentive and this revised variable was used in subsequent analyses.

Conceptually related items were collapsed into composite indices for further analysis, to improve the efficiency of logistic models. A “physical harm” index (vaccine might contain AIDS virus, vaccine could make one sick sooner, one could get AIDS from the vaccine, handicap or death could result from the trial, concern about injection related side effects) and a “social harm” index (participation would give appearance of having AIDS virus, a partner might refuse sex) resulted from this data reduction. Items that represented “tangible incentives” (that is, wanting lump sum payment, health insurance, medical care, or financial reimbursement of expenses as incentives for joining a vaccine trial) also were collapsed into a single index. “Yes” and “not sure” responses were treated as affirmative endorsements of concerns, while only “yes” responses were treated as affirmative responses for “incentives.”

Table 3 summarises univariate odds ratios and 95% confidence intervals for concerns and incentives in relation to willingness to participate in HIV-1 vaccine trials. Concern about family influence produced the largest negative odds ratio in relation to willingness, although concerns about social and physical harm, as well as practical considerations also had significant negative associations with willingness. Among incentives, helping Thai society and gaining social recognition yielded the largest odds ratios, although differences in the sizes of the individual odds ratios and associated confidence intervals were small. Wanting no incentive was not significantly related to willingness to participate.

HIV-1 RISK RELEVANT BEHAVIOUR, ATTITUDES, AND KNOWLEDGE

Table 4 summarises univariate odds ratios and 95% confidence intervals for HIV-1 risk relevant behaviour, attitudes, and knowledge, in relation to willingness to participate in
HIV-1 vaccine trials. Recent sexual behaviour had little association with willingness, except for sex with girlfriend.

Negative attitudes toward condoms, based on an additive composite scale of eight dichotomous (agree or disagree) items; (KR20 = 0.70) were unrelated to willingness. The scale items included condoms cannot provide 100% protection, condoms reduce sexual pleasure, sex workers do not like condoms, girlfriends do not like condoms, wives do not like condoms, condoms are too expensive to use regularly, condoms only used when a partner requests them, request to use condoms suggests that partner is HIV+, and condoms sex last longer (scored negatively). In contrast, intending to use condoms less, if enrolled in a trial, was significantly associated with less willingness.

Endorsments of casual contact as a source of HIV-1 exposure (sharing crockery, breathing near an HIV+ person, coughing or sneezing by an HIV infected person, mosquitoes carrying infected blood from person to person, deep kissing) were associated with somewhat increased willingness to participate. The small number of recruits with errors in transmission knowledge (that is, not recognising commonly accepted routes of transmission) also were significantly more willing to participate.

Inconsistent condom use with CSW and girlfriends was investigated, but has not been included in the table, because these analyses are complex, and over-lapping, subsets of the sample. Inconsistent condom use with CSW occurred among 23.6% of those who reported CSW partners, but was not significantly associated with willingness to participate (p = 0.16; OR = 0.76, 95% CI = 0.52–1.12). Inconsistent condom use with girlfriends was reported by 67.6% of those with girlfriend partners and was not significantly related to willingness to participate in a trial (p = 0.45; OR = 0.91, 95% CI = 0.70–1.17).

WILLINGNESS TO PARTICIPATE: MULTIVARIATE MODEL

In the multivariate model (Table 5), the largest odds ratios were produced by a conceptually diverse set of variables which included: perceived risk, the desire to help Thai society, residence in northeastern Thailand, errors in transmission knowledge, desire for tangible incentives, and the intention to use condoms less often if enrolled in a trial. Other significant correlates of increased willingness included endorsement of casual contact as a means of HIV-1 transmission and relatively low education, while the desire to receive recognition from family or friends yielded a nearly significant trend. It is notable that the direction of the association between willingness and intentions to use condoms less often in a vaccine trial was the reverse of that found in the univariate analysis.

Factors which appeared to inhibit willingness to participate in trials included concern that family members would not want them to join a trial and concerns about possible physical harm from trial participation. Concern with social harm yielded a nearly significant trend, while concerns about time required by the study and the need to sign a consent form were not significantly related to willingness.

Discussion

This study found that nearly one third of participants would “definitely” be willing to join an HIV-1 vaccine trial. The multivariate model indicated a mix of associated motivations, whereby “altruism” (that is, wanting to help Thai society) existed side by side with a desire for “tangible gain” and/or social recognition. Worries about HIV-1 exposure adversely affected willingness, as did the possible opportunity to reduce the use of condoms. Anticipated social pressure from family exerted a substantial counterweight against participation.

Table 4 Univariate analysis of recent HIV risk relevant behaviour, attitudes, and knowledge as associated with willingness to join an HIV vaccine trial (n=2670)

<table>
<thead>
<tr>
<th>Factor</th>
<th>Odds Ratio (OR)</th>
<th>95% CI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk perception</td>
<td>1.00</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Concern—signing consent form</td>
<td>1.12</td>
<td>0.84–1.50</td>
<td>0.43</td>
</tr>
<tr>
<td>Concern—family wouldn’t want them to join</td>
<td>0.51</td>
<td>0.40–0.64</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Concern—physical harm (1+ endorsements)</td>
<td>0.62</td>
<td>0.49–0.80</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Incentive—help Thai society</td>
<td>1.33</td>
<td>0.65–1.02</td>
<td>0.07</td>
</tr>
<tr>
<td>Incentive—signing consent form</td>
<td>0.98</td>
<td>0.74–1.31</td>
<td>0.90</td>
</tr>
</tbody>
</table>

Table 5 Multivariate logistic analysis of willingness to participate, with demographic, HIV knowledge, attitudes, risk relevant behaviour, concerns, and incentives (n=2661)

<table>
<thead>
<tr>
<th>Factor</th>
<th>OR</th>
<th>95% CI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education (primary school or less)</td>
<td>1.24</td>
<td>1.00–1.53</td>
<td>0.05</td>
</tr>
<tr>
<td>Urban v rural (2 years before entering RTA)</td>
<td>0.88</td>
<td>0.73–1.07</td>
<td>0.20</td>
</tr>
<tr>
<td>Concern—signing consent form</td>
<td>1.12</td>
<td>0.84–1.50</td>
<td>0.43</td>
</tr>
<tr>
<td>Concern—family wouldn’t want them to join</td>
<td>0.98</td>
<td>0.74–1.31</td>
<td>0.90</td>
</tr>
</tbody>
</table>

*Kathoey is most easily translated as male to female transsexual person. They are regarded as a second kind of woman or “third sex” in Thailand.*
†See “HIV-1 risk relevant behaviour, attitudes, and knowledge” under “Results” for a full listing of content.
in trials and this suggested that vaccine education should go beyond informing only discrete target populations.

The association between willingness and lower educational attainment suggests the need for more attention to field testing vaccine education materials for low levels of education and ensuring that oral presentations recognise vernacular terminology and the educational level of their audience. Similar concerns were raised in a study with injection drug users (IDU) in Bangkok, where vaccine trial knowledge was evaluated after an educational programme. The findings here also indicate that vaccine trial education and counselling programmes need to continually reinforce condom use and other forms of protection and to underscore the lack of protection offered by trial participation. Accurate assessment of personal risk needs to be emphasised, along with efforts to correct misconceptions about HIV-1 transmission.

A major concern for planning HIV-1 vaccine trials has been the possibility of behavioural side effects. Unfortunately, it has been difficult to predict the frequency of unprotected intercourse and other HIV-1 exposure risks during trials, relative to behaviour at enrolment. Some vaccine feasibility studies have shown evidence of risk reduction with behavioural intervention (for example, Koblin et al.); however, studies of HIV-1 risk behaviour during preventive vaccine trials have yielded mixed results. Several studies of willingness to join trials have examined behavioural intentions, but only Meyers et al. and the present investigation have reported analyses of HIV-1 knowledge or sexual risk behaviour in relation to willingness to participate. MacQueen et al. reported a borderline significant relation between recent injection risk behaviour and willingness in Bangkok IDUs, although directionality was not noted. Most areas of recent risk relevant behaviour were unrelated to willingness to participate in the multivariate model. The main exception was sex with girlfriends, which has become increasingly common among young Thai men and was associated with diminished willingness to participate here. Perhaps because perceived risk was lower among those with girlfriend partners than among those with CSW partners (data not shown) the need for a vaccine may be less apparent to those with non-commercial partners. Another possibility is that participation may be perceived by some respondents as requiring them to change their sexual behaviour, which may be unattractive. This hypothesis becomes more tenable when one also considers the borderline significant univariate association between decreased willingness and recent sex with a commercial sex worker (CSW). However, sex with a CSW was not included in the final multivariate model, after an alternate analysis indicated that it was not significant when other factors were controlled.

The level of willingness to participate found in the present investigation was slightly higher than that obtained in RTA recruits from Thailand’s epicentre region in the upper north. It also was slightly higher than the levels of willingness found in female CSWs from the upper north, male STD clinic attendees from the upper north, and male and female STD clinic attendees in Bangkok. Willingness to participate was expressed by 25–29% in these cohort samples, although prevalence and incidence varied widely. One might have expected differences between this study and findings from the upper north, where data were collected at the epidemic’s peak and prevalence was severalfold higher. Greater willingness was expressed by in-treatment Bangkok IDUs, who represented a population with stable and much higher prevalence. Even so, comparisons among studies suggest that the association between prevalence and willingness is not necessarily linear. For example, the Bangkok IDU reported more willingness than CSW in Thailand’s upper north, who had similar prevalence and resided in a higher prevalence city.

The similarity in levels of willingness to participate among this study and most other investigations in Thailand also is of interest with regard to the data collection methodology. The self administered questionnaire format might be expected to yield less willingness and more frequent expression of concerns relative to interview studies in Thailand because interviews may tend to elicit acquiescent response biases. The level of willingness here was much higher than that reported by Bangkok health facility workers; however, that sample was not assumed to be at high risk, no serological data were collected, and the sample was composed of hospital personnel whose socioeconomic status (SES) tended to be much higher than in the present investigation. Willingness was less than that reported in a clinic based study of Bangkok IDU which provided more targeted HIV-1 vaccine education (which concerned a specific vaccine product) and used self administered questionnaires.

Compared with most other investigations in Thailand, specific concerns about social discrimination and possible side effects (short term and long term) were reported less often. Even so, most participants endorsed at least one area of concern regarding physical harm, and worries about “social harm” also were common. Levels of concern were similar to those expressed in a study of Bangkok IDU.

One can speculate that a number of factors may overrule apparently “straightforward” motivators of willingness. Data from this study were collected after the completion of Thailand’s first three vaccine trials and it might be assumed that this has diminished public fears about trials. The relatively low frequency of specific concerns about trials might reflect this, although one might have expected that willingness would be much higher than in previous investigations. Although sociodemographic variables were of limited importance here, they have proved important in studies where more variance in these variables has been present. For example, sex differences have been particularly important in a number of investigations with high risk populations in Thailand and
other countries, where the greater willingness of women to join trials may have reflected their limited control over other means of protection. The only other study to investigate educational level also found that willingness was greater among less educated participants, as was the case here.

The present investigation is the only study in Thailand which has investigated regional differences. It is unclear how cultural differences might have affected the willingness of participants who had been living in northeastern Thailand before entering the RTA, although this would be worthy of further investigation. A related factor could be language because the spoken language in this region is Lao, rather than central Thai ("standard" Thai), although the two are closely related. On the other hand, educational instruction, mass media, and almost all forms of written language in northeastern Thailand occur in central Thai. In addition, extended migration to Bangkok and other central Thai locales from this region is commonplace and may have occurred among those who had resided in the north east before induction. If language were a consideration, one also might have expected that participants from the south would show differences compared with those from central Thailand, because they speak a distinctive dialect; however, this was not the case.

The type and amount of information provided to study participants may be another factor affecting willingness. Studies conducted outside of Thailand have shown the direct effects of these variables on willingness to participate in trials. Providing more information (for example, introducing the typical double blind placebo design) has been associated with reduced willingness, as has pointing out possible side effects. The present investigation did not provide an experimental test of how education affects willingness to join trials, and so it is necessary to be guarded about inferences drawn from the data regarding vaccine education. Two different instructional methods were used; however, there were no differences on willingness or key variables between them.

While specific concerns about vaccine trials were expressed less often than in other Thai studies, the level of willingness was similar to most other studies drawn from populations under study for vaccine trials. Concerns were similar in their prevalence to those obtained in a study of Bangkok IDU where education was provided regarding a specific vaccine product and overall willingness was greater. Hence, the role of education with respect to willingness is not entirely clear although it would seem to mitigate some vaccine related worries.

Overall, when one considers results from this study, as well as those from other work in Thailand and elsewhere, several implications are evident. General education programmes about vaccine trials may not fully address misconceptions about trials (for example, limits of disease protection) and more attention needs to be given to specific concerns and towards ensuring that material is well matched to public understanding and comprehension of vaccine related issues. While there is some evidence from other research that the provision of information may reduce initial willingness to participate in trials, it would appear that substantial numbers of people are willing to volunteer for trials even after fairly detailed education has been provided. Still, the role of educational interventions needs to be more rigorously evaluated so that trial planners can more efficiently deliver their vaccine education messages and better estimate any attrition that may occur in response to education. Future studies also need to be designed to better identify demographic, informational, and methodological factors that may moderate willingness to join trials and that have implications for the planning and promotion of trials.

The relatively similar levels of willingness to participate in trials across studies of young adults from lower SES backgrounds (including this one) regardless of method, geography, local prevalence, and risk behaviour would suggest that the present investigation may have some generalisation, although the somewhat lower levels of physical and social concerns may have less generalisability than the overall level of willingness to participate in trials. Sample differences between investigations of willingness and actual vaccine trials make it difficult to generalise from one line of research to other. Vaccine trials have generally been conducted in urban areas and have enrolled either in-treatment IDU or low risk individuals who are older and more educated and of higher SES backgrounds than those in this and other investigations of willingness.

Findings from vaccine trials that report data on study recruitment suggest that multiple methods of recruitment may be necessary and that a substantial number of prospective volunteers do not pursue pretrial medical and behavioral screening. In addition, a minority of people who are screened decline to join or are lost to follow up. Once enrolled, it appears that very high levels of retention have been achieved. Findings from trials would suggest that willingness to take part in trials may be somewhat “soft” and becomes challenged by the recruitment process. None the less, trials have proved feasible and attrition during recruitment may be declining over time.

As samples used in cohort preparation studies begin to be used for recruited for actual trials (see Graham et al. and MacQueen et al. for examples) evaluation of whether attitudes, motivations, and opinions about vaccine trial participation predict recruitment, compliance, and risk relevant behaviour can occur. The predictive validity of these variables also can be evaluated with surrogate outcomes, such as enrolment into non-HIV-1 trials (see Tello et al. for an example, in which willingness to join HIV-1 vaccine trials corresponded highly with enrolment into a genital herpes vaccine trial). Targeted education, attention to methodology, and moderating variables, as well as efforts to evaluate predictive validity, may increase the usefulness of attitudes towards trial participation in the planning of future trials.
The opinions and ascertainments expressed herein do not nec-
essarily reflect those of the US Department of Defense, the Royal Thai Army Medical Department, and the Henry M Jack-
son Foundation.

We are indebted to the individual soldiers who made this stu-
dy possible, our field staff, our data analyst, and institutional
support provided by the Royal Thai Army, the US Army, and the Henry M Jackson Foundation. We wish to thank Phil Ren-
zullo and two anonymous reviewers for their helpful comments on an earlier draft of this manuscript.

Preparation of this manuscript was supported by Cooperative
Agreement NO DAMD17–93-V-3004 between the US Army
Medical Research and Materiel Command and the Henry M
Jackson Foundation for the Advancement of Military Medicine.
Contributors: RAJ, KT, LEM, and CJM were the principal
investigators and were responsible for study design, question-
naire design, and data analysis, as well as participating in study
implementation. VJ was the principal investigator for the study
site and contributed to the study design, as well as overseeing
study implementation. AEB and SN participated in study over-
sight and assisted with manuscript preparation. SN also assisted
with the vaccine education component of the study.

1 Barthelow BN, MacQueen KM, Douglas JM, et al. Assess-
ment of changing willingness to participate in phase III
HIV vaccine trials among men who have sex with men. J

2 Celentano DD, Beyrer C, Narpratan C, et al. Willingness
to participate in AIDS vaccine trials among high risk popula-
tions in Northern Thailand. J Acquir Immun Defic Syndr

3 Siripasna N, Markowitz LE, Tungskul V, et al. Willingness
to participate in HIV vaccine trials in Thailand. 4th Inter-
national Congress on AIDS in Asia and the Pacific Manila.
October 1997 [abstract C(3)145].


vaccine trials in high risk heterosexual cohorts in

disincentives to participate in prophylactic HIV

Trials to participate in HIV vaccine efficacy trials in the

8 MacQueen KM, Vanichsen S, Kitayaporn D, et al. Willing-
ness of injection drug users to participate in an HIV
vaccine efficacy trial in Bangkok, Thailand. J Acquir

HIV vaccine efficacy trials be possible with female injection

10 Tello J, Soong S-J, Hunter B, et al. HIV vaccine acceptance
among heterosexual clients of a sexually transmitted

11 Research Institute for Health Sciences, The Center for Pub-
lic Health Research, Chiang Mai University: Preparations
for AIDS vaccine evaluations in Northern Thailand

cohort study of HIV-1 infection in young men in the Royal
Thai Army. 12th World AIDS Conference (Abstract no

13 Celentano DD, Bond KC, Lyles CM, et al. Preventive inter-
vention to reduce sexually transmitted infections: a field
trial in the Royal Thai Army. Ann Intern Med 2000;160:
535–40.

14 Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed.

15 Celentano DD, Nelson KE, Suprasert S, et al. Dynamics of
risk behavior for HIV infection among young Thai men. J

16 Beyrer C. War in the blood. London, New York: Zed Books,
1998.

17 Koblin BA, Taylor PA, Avrett S, et al. The feasibility of
HIV-1 vaccine efficacy trials among gay/bisexual men in
61.

18 Chesney MA, Chambers DB, Kahn JO. Risk behavior for
HIV infection in participants in preventive HIV vaccine

19 McElrath MJ, Montefiori D, Wolfit M, et al. Safety, immu-
nity, and risk behavior in HIV-1 uninfected volunteers rep-
resenting diverse risk populations following recombinant
envelope vaccinations: a three year follow-up. XI Inter-

20 Thapinta D, Jenkins RA, Celentano DD, et al. Evaluation of
behavioral and social issues in Thai HIV vaccine trial

21 Nelson KE, Celentano DD, Tungskul S. Changes in
sexual behavior and a decline in HIV infection among

22 Fowler FJ. Survey research methods. 2nd ed. Newbury Park,

National migration survey of Thailand. (IPSRI Publication
No 168), Salaya, Nakorn Pathom, Thailand: Institute for
Population and Social Research, Mahidol University, 1995.

behaviours and comprehension among intravenous drug
users volunteered for HIV vaccine trial. J Med Assoc Thail-

25 Jenkins RA, Chaiwaworopong S, Morgan PA, et al. Recruiting
and screening volunteers for a Phase I/II HIV-1 vaccine
7.

26 Phanuphak P, Pteeratkulpixarn S, Sarangbin S, et al. Inter-
national clinical trials of vaccines: I. Phase I trial of an
HIV-1 vaccine in Thailand. J Acquir Immun Defic Syndr

27 Thapinta D, Jenkins RA, Chaddic C, et al. Volunteer
recruitment for prophylactic HIV vaccine trial in Thailand.
5th International Conference on AIDS in Asia and the

28 Graham BS, McElrath MJ, Conner, RI, et al. Analysis of
tivaccine trials among gay/bisexual men in
61.

29 Chesney MA, Chambers DB, Kahn JO. Risk behavior for
HIV infection in participants in preventive HIV vaccine

30 McElrath MJ, Montefiori D, Wolfit M, et al. Safety, immu-
nity, and risk behavior in HIV-1 uninfected volunteers rep-
resenting diverse risk populations following recombinant
envelope vaccinations: a three year follow-up. XI Inter-

31 Thapinta D, Jenkins RA, Celentano DD, et al. Evaluation of
behavioral and social issues in Thai HIV vaccine trial

32 Nelson KE, Celentano DD, Tungskul S. Changes in
sexual behavior and a decline in HIV infection among

33 Fowler FJ. Survey research methods. 2nd ed. Newbury Park,

National migration survey of Thailand. (IPSRI Publication
No 168), Salaya, Nakorn Pathom, Thailand: Institute for
Population and Social Research, Mahidol University, 1995.

behaviours and comprehension among intravenous drug
users volunteered for HIV vaccine trial. J Med Assoc Thail-

36 Jenkins RA, Chaiwaworopong S, Morgan PA, et al. Recruiting
and screening volunteers for a Phase I/II HIV-1 vaccine
7.

37 Phanuphak P, Pteeratkulpixarn S, Sarangbin S, et al. Inter-
national clinical trials of vaccines: I. Phase I trial of an
HIV-1 vaccine in Thailand. J Acquir Immun Defic Syndr

38 Thapinta D, Jenkins RA, Chaddic C, et al. Volunteer
recruitment for prophylactic HIV vaccine trial in Thailand.
5th International Conference on AIDS in Asia and the

39 Graham BS, McElrath MJ, Conner, RI, et al. Analysis of
tivaccine trials among gay/bisexual men in
61.